|
K.Yu. Zherebchikova, M.O. Soltakhanova, Yu.P. Sych, M.I. Sekacheva, V.V. Fadeev, M.V. Dolidze, G.A. Repetunov, A.A. Vilensky
Prevalence, risk factors and features of the course of thyroid dysfunction induced by immunotherapy for cancer
|
№2 / 2025
|
|
Xinyi Yang, Reshetov I.V., Poltavskaya M.G., Agakina Yu.S., Kulikov T.S.
Studying on the progress of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors
|
№9 / 2024
|
|
Zhurtova I.B., Aramisova L.S., Abdul Moati H.A., Arkhestova D.R., Khachmakhova E.Z.
Comparative characteristics of the incidence of various endocrinopathies in cancer patients receiving treatment with immune checkpoint inhibitors
|
№2 / 2024
|
|
F.G. Ivanova, T.I. Nikolaeva, N.I. Spiridonova, L.N. Afanasyeva, P.V. Nikiforov, T.N. Zharnikova
Clinical experience with the use of combination drug therapy in the first line treatment of metastatic non-small cell lung cancer
|
№14 / 2023
|
|
I.B. Zhurtova, L.V. Elgarova, A.M. Gubachikova
Immune-mediated endocrine adverse events during treatment with immune checkpoint inhibitors: a clinical case of nivolumab-induced thyroiditis
|
№7 / 2022
|
|
A.I. Semenova (1), S.A. Protsenko (1), G.M. Teletaeva (1), D.Kh. Latipova (1), A.V. Novik (1, 2)
Neoadjuvant immunotherapy for non-small cell lung cancer
|
№11 / 2021
|
|
S.A. Protsenko (1), A.I. Semenova (1), A.P. Oganesyan (1), E.M. Anokhina (1), A.V. Novik (1, 2)
Modern immunotherapy for kidney cancer
|
№7 / 2019
|
Русский
